ProCE Banner Activity

Pooled Post Hoc Analysis of Safety Outcomes From Phase III CARDINAL and CADENZA Trials of Sutimlimab in Cold Agglutinin Disease

Conference Coverage
Slideset

In this pooled post hoc analysis of patients with cold agglutinin disease enrolled on the phase III CARDINAL and CADENZA trials, sutimlimab was well tolerated, with few patients developing a serious adverse event possibly related to treatment.

Released: December 14, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.